Literature DB >> 1699772

In vivo changes of hemopoietic progenitors and the expression of the interleukin 5 gene in eosinophilic mice infected with Toxocara canis.

Y Yamaguchi1, T Matsui, T Kasahara, S Etoh, A Tominaga, K Takatsu, Y Miura, T Suda.   

Abstract

It has been demonstrated that purified recombinant interleukin 5 (rIL-5) supports the terminal differentiation and proliferation of eosinophilic precursors in vitro and plays an important role in increasing the functional activities of eosinophils. In this study, we examined the hemopoietic changes and analyzed murine (m) IL-5 mRNA expression in eosinophilic mice infected with the helminth Toxocara canis. In eosinophilic mice, eosinophils increased in number in both bone marrow and spleen. However, the number of eosinophilic precursors increased markedly in spleen cells of eosinophilic mice but remained relatively constant in the bone marrow. In the presence of granulocyte colony-stimulating factor (G-CSF), the number of granulocytic precursors increased in the spleen cells of eosinophilic mice. From these findings, the condition of eosinophilopoiesis in eosinophilic mice is accompanied by an increase in granulocyte-macrophage progenitors as well as eosinophil progenitors. Using Northern blot analysis, a weak but definite band corresponding to mIL-5 mRNA was detected in spleen cells of mice 4 and 5 days after helminthic infection. In addition, these data were confirmed by in vitro polymerase chain reaction (PCR) amplification of mRNA obtained from these spleen cells. Finally, injections of a monoclonal antibody against mIL-5 completely suppressed the blood eosinophilia in mice infected with T. canis. In conclusion, IL-5 is suggested to play a major role in eosinophilopoiesis in vivo.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1699772

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  8 in total

1.  The role of interleukin-5 in protective immunity to Strongyloides venezuelensis infection in mice.

Authors:  M Korenaga; Y Hitoshi; N Yamaguchi; Y Sato; K Takatsu; I Tada
Journal:  Immunology       Date:  1991-04       Impact factor: 7.397

2.  Eosinophilia, parasite burden and lung damage in Toxocara canis infection in C57Bl/6 mice genetically deficient in IL-5.

Authors:  M Takamoto; K S Ovington; C A Behm; K Sugane; I G Young; K I Matthaei
Journal:  Immunology       Date:  1997-04       Impact factor: 7.397

3.  Occurrence of interleukin-5 production by CD4- CD8- (double-negative) T cells in lungs of both normal and congenitally athymic nude mice infected with Toxocara canis.

Authors:  M Takamoto; Y Kusama; K Takatsu; H Nariuchi; K Sugane
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

4.  Regulation of primary Strongyloides ratti infections in mice: a role for interleukin-5.

Authors:  K S Ovington; K McKie; K I Matthaei; I G Young; C A Behm
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

5.  Mechanisms of eosinophilia in BALB/c-nu/+ and congenitally athymic BALB/c-nu/nu mice infected with Toxocara canis.

Authors:  Y Kusama; M Takamoto; T Kasahara; K Takatsu; H Nariuchi; K Sugane
Journal:  Immunology       Date:  1995-03       Impact factor: 7.397

6.  Molecular basis of a high affinity murine interleukin-5 receptor.

Authors:  R Devos; G Plaetinck; J Van der Heyden; S Cornelis; J Vandekerckhove; W Fiers; J Tavernier
Journal:  EMBO J       Date:  1991-08       Impact factor: 11.598

7.  Identification of eosinophil lineage-committed progenitors in the murine bone marrow.

Authors:  Hiromi Iwasaki; Shin-ichi Mizuno; Robin Mayfield; Hirokazu Shigematsu; Yojiro Arinobu; Brian Seed; Michael F Gurish; Kiyoshi Takatsu; Koichi Akashi
Journal:  J Exp Med       Date:  2005-06-13       Impact factor: 14.307

8.  Immunopathological changes in the brain of immunosuppressed mice experimentally infected with Toxocara canis.

Authors:  Mohamed M Eid; Samy I El-Kowrany; Ahmad A Othman; Dina I El Gendy; Eman M Saied
Journal:  Korean J Parasitol       Date:  2015-02-27       Impact factor: 1.341

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.